CINECA IRIS Institutional Research Information System
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, progetti, pubblicazioni, attività) adottato dall'Università degli Studi di Torino.
AperTO è l'archivio istituzionale Open Access destinato a raccogliere, rendere visibile e conservare la produzione scientifica dell'Università degli Studi di Torino.
EnglishSurvival predictions are currently determined on the basis of NRAS/BRAF mutations, even though TERT promoter mutations have been recently associated with a poor prognosis in stage I-II melanomas. Usually, it is not recommended to perform a mutational test on primary melanoma, as the results do not always reflect the mutational status of metastases. In particular, trunk melanomas have been reported to have an unfavourable prognosis. A series of 105 advanced melanoma patients were analysed by TERT promoter Sanger sequencing. Univariate/multivariate binarylogisticregressionmodelswereperformedusingprogressiontoavisceralsiteasthedependent variable and patient/tumour characteristics as covariates. Performance of the model was assessed in an external independent primary melanoma patients’ dataset. Male gender (odds ratio (OR), 344; 95% CI, 1.12–10.6; p = 0.031), AJCC (American Joint Committee on Cancer) classification (OR, 022; 95% CI, 0.07–0.67; p = 0.008), SLNB (Sentinel Lymph Node Biopsy) status (OR, 3.05; 95% CI, 1.06–8.78; p = 0.039) and TERT-mutated trunk lesions (OR, 3.78; 95% CI, 1.35–10.6; p = 0.011) were significantly associated with the risk of developing a visceral spreading as first site of progression usingmultivariatelogisticregressionanalysis. Theseresultswereconfirmedintheexternalvalidation controlgroup. Therefore,intrunkprimarymelanomas,duetotheirhighriskofprogressiontovisceral sites, we encourage somatic TERT mutation analysis at diagnosis to identify those patients who wouldpotentiallybenefitfromamoreintensivefollow-upprotocolandapromptinitiationoftherapy.
| Titolo: | TERT Promoter Mutations are Associated with Visceral Spreading in Melanoma of the Trunk |
| Autori Riconosciuti: | |
| Autori: | Simona Osella-Abate, Luca Bertero, Rebecca Senetta, Sara Mariani, Francesco Lisa, Vittoria Coppola, Jasna Metovic, Barbara Pasini, Susana Puig, Maria Teresa Fierro, Esperanza Manrique-Silva, Rajiv Kumar, Eduardo Nagore, Paola Cassoni, Simone Ribero. |
| Data di pubblicazione: | 9999 |
| Abstract: | Survival predictions are currently determined on the basis of NRAS/BRAF mutations, even though TERT promoter mutations have been recently associated with a poor prognosis in stage I-II melanomas. Usually, it is not recommended to perform a mutational test on primary melanoma, as the results do not always reflect the mutational status of metastases. In particular, trunk melanomas have been reported to have an unfavourable prognosis. A series of 105 advanced melanoma patients were analysed by TERT promoter Sanger sequencing. Univariate/multivariate binarylogisticregressionmodelswereperformedusingprogressiontoavisceralsiteasthedependent variable and patient/tumour characteristics as covariates. Performance of the model was assessed in an external independent primary melanoma patients’ dataset. Male gender (odds ratio (OR), 344; 95% CI, 1.12–10.6; p = 0.031), AJCC (American Joint Committee on Cancer) classification (OR, 022; 95% CI, 0.07–0.67; p = 0.008), SLNB (Sentinel Lymph Node Biopsy) status (OR, 3.05; 95% CI, 1.06–8.78; p = 0.039) and TERT-mutated trunk lesions (OR, 3.78; 95% CI, 1.35–10.6; p = 0.011) were significantly associated with the risk of developing a visceral spreading as first site of progression usingmultivariatelogisticregressionanalysis. Theseresultswereconfirmedintheexternalvalidation controlgroup. Therefore,intrunkprimarymelanomas,duetotheirhighriskofprogressiontovisceral sites, we encourage somatic TERT mutation analysis at diagnosis to identify those patients who wouldpotentiallybenefitfromamoreintensivefollow-upprotocolandapromptinitiationoftherapy. |
| Pagina iniziale: | 452 |
| Pagina finale: | 465 |
| Digital Object Identifier (DOI): | 10.3390/cancers11040452 |
| Parole Chiave: | TERT promoter; trunk; melanoma; visceral metastases |
| Rivista: | CANCERS |
| Appare nelle tipologie: | 03A-Articolo su Rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| cancers-11-00452.pdf | 2 PDF Editoriale | Open Access Visualizza/Apri |
Copyright © 2019